ifinatamab deruxtecan
Selected indexed studies
- Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. (J Clin Oncol, 2026) [PMID:41086386]
- Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. (Expert Opin Investig Drugs, 2025) [PMID:40418751]
- IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. (Future Oncol, 2025) [PMID:41055143]
_Worker-drafted node — pending editorial review._
Connections
ifinatamab deruxtecan is a side effect of
Sources
- Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. (2026) pubmed
- Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. (2025) pubmed
- IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. (2025) pubmed
- Antibodies to watch in 2026. (2026) pubmed
- Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. (2026) pubmed
- Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review. (2025) pubmed
- Small cell lung cancer (SCLC): At the door of targeted therapies. (2025) pubmed
- Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes. (2025) pubmed
- Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. (2023) pubmed
- ADCs and TCE in SCLC Therapy: The Beginning of a New Era? (2025) pubmed